


EQUITY RESEARCHPRICE TARGET CHANGE

Financial Services

SURG - NASDAQ	August 3, 2022
Closing Price 8/2/22 Rating: 12-Month Target Price: 52-Week Range: Market Cap (M): Shares O/S (M): Float: Avg. Daily Volume (000): Debt (M): Dividend: Dividend Yield: Risk Profile: Fiscal Year End:	\$6.80 Buy (prior \$8.00) \$10.00 \$1.76 - \$7.50 83.3 12.2 92.1% 141.8 \$6.1 \$0.00 0.0% Speculative December

Revenue ('000)								
	2021A	2022E	2023E					
1Q	10,989	21,141A	40,870					
2Q	11,378	27,720	43,570					
3Q	14,538	33,970	46,270					
4Q	14,156	41,120	48,970					
CY	51,061	123,951	179,680					
Prior	_	125,751						

GAAP EPS								
	2021A	2022E	2023E					
1Q	(1.85)	(0.10)A	0.63					
2Q	(0.07)	(0.04)	0.69					
3Q	(0.51)	0.33	0.76					
4Q	(0.79)	0.73	0.82					
CY	(3.09)	0.91	2.91					
Prior		1.06	_					



Company description: SurgePays is a technology and telecommunications company focused on the underbanked and underserved communities.

Michael Diana

(212) 895-3641 mdiana@maximgrp.com

SurgePays, Inc.

Buy

Near-Term Sign-Ups Below Our Forecast, Longer-Term Outlook and 2023 Estimates Unchanged; Raise PT to \$10 – Reiterate Buy

Summary

- SURG disclosed 150,000 ACP customers as of mid-July; this is below our forecast due to later expansion than we expected to 50 states (from 14 states)
- Based on this lag, we lower our 2Q22 estimates. We also lower our 2022 estimates: we do not expect the customer count to catch up to our current forecast until year-end 2022.
- We maintain our 2023 estimates and longer-term outlook and raise our price target to \$10, from \$8. Trading at only 2.3x our 2023 EPS estimate, SURG shares are very undervalued, in our view. Our new \$10 price target equates to a 2023E P/E of only 3.4x (previously 2.7x), a very substantial discount to peers.

Details

Mid-July ACP customer count was below our forecast... On 7/14, SURG disclosed that it had exceeded 150,000 customers in the U.S. Government's Affordable Connectivity Program (ACP). This represents very rapid growth, from 0 customers in August 2021, but is below our comparable forecast of about 170,000 customers. The reason is that we had assumed that SURG's sign-up network would be expanded to 50 states (from 14 states) and fully utilized sooner than actually occurred. On 4/7/22, SURG announced the acquisition of Torch Wireless, which extended authorization into all 50 states, but SURG did not immediately pursue signups in all of these states. In addition, management has indicated that, while demand is robust, it has had to periodically slow sign-ups due to lack of financing for computer tablets (that are given 'free' with all sign-ups). Therefore, our 2Q22 estimates (and our 2022 estimates) are probably aggressive (see below).

...but our 2022 year-end customer count outlook remains unchanged. With an expanded sign-up network and active pursuit of customers in increasingly more states, we expect SURG to catch up to our year-end customer count forecast of more than 225,000. Management has said that it expects to "easily surpass" its year-end 2022 guidance of 200,000 customers. In addition, management has indicated that tablet financing should become less of an issue with a line of credit secured by U.S. Government receivables. These actions, in our view, would also position SURG to meet (or beat) our current 2023 estimates, which we are not changing.

We lower our 2022 EPS estimate to \$0.91, from \$1.06, and make our quarterly estimates more back-end-loaded. Most impacted are our 2Q22 estimates: we are now estimating a 2Q22 net loss of (\$0.04) vs. positive EPS of \$0.10 previously. We expect an accelerating pace of sign-ups and, given this pace, it is difficult to predict in which quarter the related revenues and earnings will fall.

We maintain our 2023 estimates and raise our price target to \$10 from \$8. At a 7/27/22 Virtual Investor Spotlight appearance, management indicated that it expects to have at least 500,000 customers by year-end 2023, which is well above our forecast of about 400,000, and bolsters our confidence in our 2023 EPS estimate of \$2.91. This confidence enables us to raise our price target to \$10, which equates to a 2023E P/E multiple of only 3.4x (previously 2.7x) versus 12.8x for the average of wireless providers, 4.2x for non-prime financial services companies, 11.8x for payments companies, and 18.9x for convenience stores. These very substantial discounts could partly be explained by SURG's early stage of growth.

We reiterate our Buy rating. In the next four quarters, we expect stock price appreciation of 47% (to our \$10 price target).

We expect SURG to report 2Q22 results during the week of 8/8 (next week).

SURGEPAYS, INC. (SURG)

Income Statement															
(\$ in thousands)	1Q21A	2Q21A	3Q21A	4Q21A	1Q22A	2Q22E	3Q22E	4Q22E	1Q23E	2Q23E	3Q23E	4Q23E	2021A	2022E	2023E
Revenues	10,989	11,378	14,538	14,156	21,141	27,720	33,970	41,120	40,870	43,570	46,270	48,970	51,061	123,951	179,680
Cost of Revenues	9,857	10,051	12,635	12,348	18,508	24,292	26,632	28,972	29,373	31,314	33,254	35,195	44,891	98,404	129,136
Gross Profit	1,132	1,327	1,903	1,808	2,633	3,428	7,338	12,148	11,497	12,256	13,016	13,775	6,170	25,547	50,544
Gross Profit Margin	10.3%	11.7%	13.1%	12.8%	12.5%	12.4%	21.6%	29.5%	28.1%	28.1%	28.1%	28.1%	12.1%	20.6%	28.1%
General & Administrative	2,960	2,574	2,135	4,318	3,505	3,600	3,000	3,000	3,500	3,500	3,500	3,500	11,987	13,105	14,000
Depreciation and Amortization	218	180	181	180	169	169	169	169	169	169	169	169	759	676	676
Stock-Based Compensation	62	(17)	(37)	(4)	9	9	9	9	9	9	9	9	4	36	36
Total Operating Expenses	3,240	2,737	2,279	4,494	3,683	3,778	3,178	3,178	3,678	3,678	3,678	3,678	12,750	13,817	14,712
Operating Income	(2,108)	(1,410)	(376)	(2,686)	(1,050)	(350)	4,160	8,970	7,819	8,578	9,338	10,097	(5,993)	11,730	35,832
Other Income / Expense	0	0	0	2213	0	0	0	0	0	0	0	0	2213	0	0
Interest Expense	(1,304)	(2,097)	(1,237)	(2,880)	(169)	(169)	(169)	(169)	(169)	(169)	(169)	(169)	(7,518)	(676)	(676)
Non-Recurring Gains/Losses	(1,403)	3,293	(45)	(4,078)	(25)	0	0	0	0	0	0	0	(2,233)	(25)	0
Total Other Income	(2,707)	1,196	(1,282)	(4,745)	(194)	(169)	(169)	(169)	(169)	(169)	(169)	(169)	(7,538)	(701)	(676)
Income Before Taxes	(4,815)	(214)	(1,658)	(7,431)	(1,244)	(519)	3,991	8,801	7,650	8,409	9,169	9,928	(13,531)	11,029	35,156
Income Taxes	0	0	0	0	(32)	0	0	0	0	0	0	0	0	(32)	0
Taxes as % of Income Before Taxes	0%	0%	0%	0%	3%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Net Income (After Noncontrolling Interest)	(4,815)	(214)	(1,658)	(7,431)	(1,212)	(519)	3,991	8,801	7,650	8,409	9,169	9,928	(13,531)	11,061	35,156
Preferred Stock Dividends	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income Attributable to Common	(4,815)	(214)	(1,658)	(7,431)	(1,212)	(519)	3,991	8,801	7,650	8,409	9,169	9,928	(13,531)	11,061	35,156
Add: Interest Expense	1,304	2,097	1237	2880	169	169	169	169	169	169	169	169	3,840	676	676
Add: Non-Cash/Non-Recurring Charges	0	0	0	0	25	-400	600	600	0	0	0	0	5029	825	0
Add: Amortization of Intangible Assets	218	180	181	181	169	169	169	169	169	169	169	169	760	676	676
Add: Stock-Based Compensation	62	(17)	(37)	(4)	9	9	9	9	9	9	9	9	4	36	36
Add: Income Taxes	0	0	0	0	(32)	0	0	0	0	0	0	0	0	-32	0
Adjusted EBITDA	(3,231)	2,046	(277)	(4,374)	(872)	(572)	4,938	9,748	7,997	8,756	9,516	10,275	(3,898)	13,242	36,544
Shares Outstanding (EOP)	2,543	3,230	3,288	12,100	12,100	12,100	12,100	12,100	12,100	12,100	12,100	12,100	12,100	12,100	12,100
Shares Outstanding (Average)	2,604	3,088	3,264	9,404	12,100	12,100	12,100	12,100	12,100	12,100	12,100	12,100	4,382	12,100	12,100
GAAP EPS	-1.85	-0.07	-0.51	-0.79	-0.10	-0.04	0.33	0.73	0.63	0.69	0.76	0.82	-3.09	0.91	2.91
Dividends per Share	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Adjusted EBITDA Per Share	-1.24	0.66	-0.08	-0.47	-0.07	-0.05	0.41	0.81	0.66	0.72	0.79	0.85	-0.89	1.09	3.02
•															

Source: Company reports and Maxim Group estimates

Maxim Group LLC 2

DISCLOSURES



Maxim Group LLC Ratings Distribution As of: 08/02/22						
		% of Coverage Universe with Rating	% of Rating for which Firm Provided Banking Services in the Last 12 months			
Buy	Fundamental metrics and/or identifiable catalysts exist such that we expect the stock to outperform its relevant index over the next 12 months.	90%	44%			
Hold	Fundamental metrics are currently at, or approaching, industry averages. Therefore, we expect this stock to neither outperform nor underperform its relevant index over the next 12 months.	10%	48%			
Sell	Fundamental metrics and/or identifiable catalysts exist such that we expect the stock to underperform its relevant index over the next 12 months.	0%	0%			
	*See valuation section for company specific relevant indices					

I, Michael Diana, attest that the views expressed in this research report accurately reflect my personal views about the subject security and issuer. Furthermore, no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report.

The research analyst(s) primarily responsible for the preparation of this research report have received compensation based upon various factors, including the firm's total revenues, a portion of which is generated by investment banking activities.

Maxim Group makes a market in SurgePays, Inc.

Maxim Group managed/co-managed/acted as placement agent for an offering of the securities for SurgePays, Inc. in the past 12 months.

Maxim Group has received the non-objecting beneficial owners (NOBO) list from SurgePays, Inc. which may have some value for the Firm's Wealth Management division.

Maxim Group received compensation for investment banking services from SurgePays, Inc. in the past 12 months.

An affiliate of Maxim Group beneficially owns warrants/shares in SurgePays, Inc. .

SURG: For SurgePays, Inc., we use the Russell 2000 Index (RUT) as the relevant index.

Valuation Methods

SURG: We value SurgePays, Inc. based on relative valuation, primarily using multiples of estimated EPS, and, secondarily, multiples of estimated revenues.

Maxim Group LLC 3

Price Target and Investment Risks

SURG: Aside from general market and other economic risks, and aside from COVID (which is a risk for all companies), risks particular to our price target and rating for SurgePays, Inc. include: 1) competition (from wireless providers, financial services companies and other companies); 2) governmental/regulatory risk (particularly related to the FCC's ACP program); 3) execution of SurgePays' sales force growth plan; 4) technology risk (particularly relating to hardware and proprietary software); 5) funding/equity risk (related to inability to obtain debt or equity funding and to ownership or earnings dilution from obtaining funding at an unfavorable price or on unfavorable terms).

RISK RATINGS

Risk ratings take into account both fundamental criteria and price volatility.

Speculative – <u>Fundamental Criteria:</u> This is a risk rating assigned to early-stage companies with minimal to no revenues, lack of earnings, balance sheet concerns, and/or a short operating history. Accordingly, fundamental risk is expected to be significantly above the industry. <u>Price Volatility:</u> Because of the inherent fundamental criteria of the companies falling within this risk category, the price volatility is expected to be significant with the possibility that the investment could eventually be worthless. Speculative stocks may not be suitable for a significant class of individual investors.

High – <u>Fundamental Criteria:</u> This is a risk rating assigned to companies having below-average revenue and earnings visibility, negative cash flow, and low market cap or public float. Accordingly, fundamental risk is expected to be above the industry. <u>Price Volatility:</u> The price volatility of companies falling within this category is expected to be above the industry. High-risk stocks may not be suitable for a significant class of individual investors.

Medium – <u>Fundamental Criteria:</u> This is a risk rating assigned to companies that may have average revenue and earnings visibility, positive cash flow, and is fairly liquid. Accordingly, both price volatility and fundamental risk are expected to approximate the industry average.

Low – <u>Fundamental Criteria:</u> This is a risk rating assigned to companies that may have above-average revenue and earnings visibility, positive cash flow, and is fairly liquid. Accordingly, both price volatility and fundamental risk are expected to be below the industry.

DISCLAIMERS

Some companies that Maxim Group LLC follows are emerging growth companies whose securities typically involve a higher degree of risk and more volatility than the securities of more established companies. The securities discussed in Maxim Group LLC research reports may not be suitable for some investors. Investors must make their own determination as to the appropriateness of an investment in any securities referred to herein, based on their specific investment objectives, financial status and risk tolerance.

This communication is neither an offer to sell nor a solicitation of an offer to buy any securities mentioned herein. This publication is confidential for the information of the addressee only and may not be reproduced in whole or in part, copies circulated, or disclosed to another party, without the prior written consent of Maxim Group, LLC ("Maxim").

Information and opinions presented in this report have been obtained or derived from sources believed by Maxim to be reliable, but Maxim makes no representation as to their accuracy or completeness. The aforementioned sentence does not apply to the disclosures required by FINRA Rule 2241. Maxim accepts no liability for loss arising from the use of the material presented in this report, except that this exclusion of liability does not apply to the extent that such liability arises under specific statutes or regulations applicable to Maxim. This report is not to be relied upon in substitution for the exercise of independent judgment. Maxim may have issued, and may in the future issue, other reports that are inconsistent with, and reach different conclusions from, the information presented in this report. Those reports reflect the different assumptions, views and analytical methods of the analysts who prepared them and Maxim is under no obligation to ensure that such other reports are brought to the attention of any recipient of this report.

Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Information, opinions and estimates contained in this report reflect a judgment at its original date of publication by Maxim and are subject to change without notice. The price, value of and income from any of the securities mentioned in this report can fall as well as rise. The value of securities is subject to exchange rate fluctuation that may have a positive or adverse effect on the price or income of such securities. Investors in securities such as ADRs, the values of which are influenced by currency volatility, effectively assume this risk. Securities recommended, offered or sold by Maxim: (1) are not insured by the Federal Deposit Insurance Company; (2) are not deposits or other obligations of any insured depository institution; and (3) are subject to investment risks, including the possible loss of principal invested. Indeed, in the case of some investments, the potential losses may exceed the amount of initial investment and, in such circumstances, you may be required to pay more money to support these losses.

ADDITIONAL INFORMATION IS AVAILABLE UPON REQUEST

Maxim Group LLC 4



Corporate Headquarters

New York City 300 Park Ave., 16th Floor New York, NY 10022

Tel: 212-895-3500

Capital Markets/Syndicate: 212-895-3695

Corporate Finance: 212-895-3811
Corporate Services: 212-895-3631
Equity/Options Trading: 212-895-3790

Equity Research: 212-895-3736

Fixed Income Trading: 212-895-3875

Woodbury, Long Island

100 Crossways Park Drive West Suite 207

Woodbury, NY 11797 Tel: 516-393-8300

West Palm Beach, Florida

105 South Narcissus Avenue Suite 307

West Palm Beach, FL 33401

Tel: 561-465-2605

Fort Lauderdale, Florida

1 East Broward Blvd Suite 1440 Fort Lauderdale, FL 33301 Miami Beach 555 Washington Ave., Suite 320 Miami Beach, FL 33139

Tel: 786-864-0880

Global Equity Trading: 212-895-3623

Institutional Sales: 212-895-3873

Institutional Sales Trading: 212-895-3873
Portfolio/Transition Trading: 212-895-3567

Prime Brokerage: 212-895-3723

Wealth Management: 212-895-3624

Red Bank, New Jersey

246 Maple Avenue Red Bank, NJ 07701 Tel: 732-784-1900

San Rafael, California

4040 Civic Center Drive Suite 200 San Rafael, CA 94903

Tel: 212-895-3670

Stamford, Connecticut

700 Canal Street Stamford, CT 06902